Regenerative Medicine Designation More Useful 'Tool' Than CBER’s Marks Initially Anticipated

Biologics center director was skeptical that RMAT would offer much beyond US FDA's existing breakthrough therapy pathway, but he has since come to appreciate the flexibility offered by less stringent designation criteria and leeway in the types of potential confirmatory evidence.